Drug Type AAV based gene therapy |
Synonyms A non-replicating recombinant adeno-associated virus vector serotype 8 delivering CYP4V2 gene, VGR R01, VGRR01 |
Target |
Mechanism CYP4V2 replacements(cytochrome P450 family 4 subfamily V member 2 replacements) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US), Breakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bietti Crystalline Dystrophy | Phase 1 | CN | 01 Mar 2023 |
NEWS Manual | Not Applicable | 12 | VGR-R01低剂量 | fhxcxopnvn(siyftvitwl) = yyqkdscoyc ohyhdelery (dhwghevolz ) | Positive | 10 May 2024 | |
VGR-R01中剂量 | fhxcxopnvn(siyftvitwl) = aqbjwiipdr ohyhdelery (dhwghevolz ) | ||||||
NCT05694598 (ASGCT2024) Manual | Phase 1/2 | Bietti Crystalline Dystrophy CYP4V2 biallelic mutation | 12 | VGR-R01 | jlzsipdkzn(aixwpuxxhc) = All patients experienced a treatment-emergent adverse event (TEAE) but just one eye inflammation was related to VGR-R01. zmtxxfwzws (vbswvecgaz ) | Positive | 07 May 2024 |